| Literature DB >> 33229401 |
Russell Bonneville1,2, Anoosha Paruchuri1, Michele R Wing1, Melanie A Krook1, Julie W Reeser1, Hui-Zi Chen1,3, Thuy Dao1, Eric Samorodnitsky1, Amy M Smith1, Lianbo Yu4, Nicholas Nowacki5, Wei Chen5, Sameek Roychowdhury6,3.
Abstract
Microsatellites are short, repetitive segments of DNA, which are dysregulated in mismatch repair-deficient (MMRd) tumors resulting in microsatellite instability (MSI). MSI has been identified in many human cancer types with varying incidence, and microsatellite instability-high (MSI-H) tumors often exhibit increased sensitivity to immune-enhancing therapies such as PD-1/PD-L1 inhibition. Next-generation sequencing (NGS) has permitted advancements in MSI detection, and recent computational advances have enabled characterization of tumor heterogeneity via NGS. However, the evolution and heterogeneity of microsatellite changes in MSI-positive tumors remains poorly described. We determined MSI status in 6 patients using our previously published algorithm, MANTIS, and inferred subclonal composition and phylogeny with Canopy and SuperFreq. We developed a simulated annealing-based method to characterize microsatellite length distributions in specific subclones and assessed the evolution of MSI in the context of tumor heterogeneity. We identified three to eight tumor subclones per patient, and each subclone exhibited MMRd-associated base substitution signatures. We noted that microsatellites tend to shorten over time, and that MMRd fosters heterogeneity by introducing novel mutations throughout the disease course. Some microsatellites are altered among all subclones in a patient, whereas other loci are only altered in particular subclones corresponding to subclonal phylogenetic relationships. Overall, our results indicate that MMRd is a substantial driver of heterogeneity, leading to both MSI and subclonal divergence. IMPLICATIONS: We leveraged subclonal inference to assess clonal evolution based on somatic mutations and microsatellites, which provides insight into MMRd as a dynamic mutagenic process in MSI-H malignancies. ©2020 American Association for Cancer Research.Entities:
Mesh:
Year: 2020 PMID: 33229401 PMCID: PMC7939074 DOI: 10.1158/1541-7786.MCR-19-0955
Source DB: PubMed Journal: Mol Cancer Res ISSN: 1541-7786 Impact factor: 6.333